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Abstract
Background: Observational studies are widely used in pharmacoepidemiology. Several designs can be used, in
particular self-controlled designs (case-crossover and self-controlled case series). These designs offer the advantage
of controlling for time-invariant confounders, which may not be collected in electronic healthcare databases. They
are particularly useful in pharmacoepidemiology involving healthcare database. To be valid, they require the
presence of some characteristics (key validity assumptions), and in such situations, these designs should be
preferred. We aimed at describing the appropriate use and reporting of the key validity assumptions in
self-controlled design studies.
Methods: Articles published between January 2011 and December 2014, and describing a self-controlled study
design involving electronic healthcare databases were retrieved. The appropriate use (fulfilment of key assumptions)
was studied in terms of major (abrupt onset event, rare or recurrent event, and intermittent exposure) and minor
assumptions (those for which the design can be adapted).
Results: Among the 107 articles describing a self-controlled design, 35/53 (66%) case-crossover studies, and 48/55
(87%) self-controlled case series fulfilled the major validity assumptions for use of the design; 4/35 and 14/48
respectively did not fulfill the minor assumptions. Overall, 31/53 (58%) case-crossover studies and 34/55 (62%)
self-controlled case series fulfilled both major and minor assumptions. The reporting of the methodology or the
results was appropriate, except for power calculation.
Conclusions: Self-controlled designs were not appropriately used in34% and 13% of the articles we reviewed that
described a case-crossover or a self-controlled case series design, respectively. We encourage better use of these
designs in situations in which major validity assumptions are fulfilled (i.e., for which they are recommended),
accounting for situations for which the design can be adapted.
Keywords: Pharmacoepidemiology, Self-controlled designs, Observational studies, Databases, Systematic review
Background
Pharmacoepidemiology aims at assessing the risk and
benefit of pharmaceuticals in real-world populations [1].
Computerized medical databases are increasingly being
used for real life post-marketing observational studies
[2], and have several advantages: (i) the potential for
studying a very large sample size, thereby allowing for
study of rare events or exposures; (ii) the availability of
data for older adults, children, patients with low
resources, and nursing-home residents, who are most
often under-represented in clinical trials [3]; (iii) the in-
clusion of off-label prescriptions; and (iv) data are
prospectively collected [4]. However, data are usually
collected for purposes other than research (administra-
tive or healthcare management), so the databases
frequently lack information on some potential confound-
ing factors (e.g., genetics, body mass index, smoking
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status, alcohol consumption, or medical history and
comorbidities) [2]. In this context, in which many con-
founders may not be collected, self-controlled designs are
an interesting option in observational studies of pharma-
ceuticals [5]. Self-controlled designs are based only on
cases, which then act as their own control (i.e., they con-
sist in within-patient comparison between different
periods of time). Their main advantage is that time-
invariant confounders that act multiplicatively on the
baseline rates are inherently controlled for. As Nordmann
et al. reported in a systematic review [6], these designs
mainly include the case-crossover design [7, 8] and the
self-controlled case-series [9–11] and were developed to
study the short term effect of transient-exposures and
abrupt onset events. Indeed, because of the self-matched
design, the risk estimation includes only data for patients
who switch their exposure status over time (i.e., from ex-
posed to unexposed, or vice versa). With sustained expos-
ure, the opportunity for exposed patients to become
unexposed is reduced, therefore leading to a smaller num-
ber of patients with “discordant” exposure status, and re-
duced power. Moreover, the study of sustained exposures
over longer periods is subject to time-varying confounding
that needs to be addressed. Studies of insidious-onset
events (e.g., depression, cancer, autism) are subject to
misclassification bias because of uncertainty in the onset
date of the outcome. Self-controlled designs require that
some other validity assumptions be fulfilled. For case-
crossover design, the opportunity for exposure should be
the same during the case and control time periods (e.g.,
for car crashes or the risk of alcohol consumption, the
control period should be the same day of the week,
because driving or drinking behaviour may vary from
weekdays to weekends [8, 12, 13]), and there should not
be any time trend in exposure. For self-controlled case
series, two consecutive events should be independent if
they are recurrent; the probability of further exposure
should not be affected by a previous event; and the event
should not affect the short-term mortality probability.
Because of methodological developments, these designs
have become applicable in more situations, by weakening
the assumptions they require, such as the possibility to
study time trend in exposure [14, 15], event-dependant
exposure [16, 17], inter-dependant recurrences [18], or
event-dependant observation periods [16, 19].
Several systematic reviews have examined the use and
reporting of case-crossover designs only [20], self-
controlled case series only [21] or self-controlled studies
in general [6]. Recently, we showed that self-controlled
designs are rarely used in pharmacoepidemiology [22].
We did not find any recent study focusing on the appro-
priate use of self-controlled designs in pharmacoepide-
miology involving electronic healthcare databases, with
regard to major and minor validity assumptions.
Here we aimed to assess the appropriate use of self-
controlled designs, in terms of their validity assumptions
in pharmacoepidemiology involving electronic health-
care databases and to update the Nordmann et al. review
[6]. To achieve this goal, we performed a systematic
review to describe whether the required characteristics
for the use of the designs were fulfilled and adequately
reported in published articles.
Methods
Search
For the systematic review, we searched MEDLINE via
Pubmed for English and French articles of self-
controlled studies (case-crossover or self-controlled case
series) involving electronic healthcare databases that
were published from January 1, 2011 to December 31,
2014. The search keywords are reported in Additional
file 1: S1. Papers reporting the study of safety or efficacy
of a medical product that used a self-controlled design
and involving electronic healthcare databases were
included. We excluded articles of studies not examining
a drug or device, methodological articles (design devel-
opment or study protocol), drug utilization or prescrip-
tion studies (drug utilization or drug prescription
patterns), descriptive or case-series studies (prevalence
or incidence of disease), clinical practice evaluation
(quality improvement in clinical practice), and articles
not describing a self-controlled design or not involving
electronic healthcare databases.
Data collection
The data were collected by three readers who used a
standardized extraction form (Additional file 1: S2)
based on the STROBE recommendations [23] and on
previous systematic reviews of designs in pharmacoepi-
demiology [6, 22].
The collected data focused on the characteristics of
exposures and events and on the study designs. The “ex-
posure characteristics” section contained information
about the type, prevalence and characteristic of the
exposure (i.e. one shot, such as vaccines; transient for a
few days, such as antimicrobial therapy or analgesics;
intermittent on a specified frequency, such as chemo-
therapy; or sustained, such as long term use of
hypoglycaemic agents). In several cases, we reclassified
the sustained exposures as transient, when the event of
interest was explicitly hypothesised to occur shortly after
the drug initiation (product initiation for incident user
designs), or intermittent, when we considered that a
high opportunity of switch from exposed to unexposed
status (or vice versa) can be assumed over the observa-
tion period (especially when the risk period was equal
and non-inferior1 to the prescription period). When no
classification was possible after consensus, the exposure
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classification was considered unclear. The “event charac-
teristics” section contained information about the type,
definition, prevalence or incidence, and characteristics of
the event, such as the potential for recurrence (unique,
such as hip fracture, or recurrent, such as seizures), and
its onset (abrupt, such as car crash, or insidious, such as
depression). An event was considered recurrent if it was
likely to occur several times within the same patient dur-
ing the observation period (because recurrence was
clearly reported in the article or such an event is usually
considered recurrent, such as febrile convulsions). An
event was considered rare if its prevalence in the source
study population was less than 5%. Subjective items (i.e.
type of exposure, event onset or recurrence) were
discussed among the authors to reach consensus. The
“design” section included information about the type
(self-controlled case series or case-crossover) and char-
acteristics of the study design: for case-crossover studies,
definition of time windows; opportunity for exposure
during the case and control periods, existence, reporting
and consideration in the analysis of a time trend in ex-
posure; and for self-controlled case series, independent
recurrences in case of recurrent events, independence of
exposure with respect to the event, and independence of
the short-term mortality risk with respect to the event).
Major validity assumptions
For self-controlled designs (i.e. required characteristics
that must be fulfilled for the self-controlled design to be
valid) were based on the methodological studies for the
corresponding designs [7–10]. For case-crossover stud-
ies, these characteristics are a transient or intermittent
exposure, an abrupt-onset event, and a rare event. For
self-controlled case series, they are a transient or inter-
mittent exposure, an abrupt-onset event, and a rare and/
or recurrent event.
Minor validity assumptions
For self-controlled designs (i.e. situations that can
threaten the design validity but when the design can be
adapted to be valid in light of recent methodological de-
velopments) were as follows: for case-crossover studies,
the opportunity for exposure should be the same during
the case and control time periods, and there should not
be any time trend in exposure. We considered that a
time trend existed if it was clearly reported by the
authors or, when not clearly reported, if we considered
that such trend could be suspected in the study setting
(e.g., in the study of a drug shortly after market
authorization (24) or the study of drugs during preg-
nancy especially when control periods are chosen before
pregnancy because prescription patterns change after
conception). For exposures with a time trend, we consid-
ered that the time trend was accounted for when the
authors used a case-time control design or another ap-
propriate design (such as bidirectional case-crossover
design or case-case-time-control design) [14, 15, 24, 25].
For self-controlled case series, two consecutive events
should be independent if they are recurrent; otherwise
the design should be adapted as appropriate, as in con-
sidering only the first event [10, 18]. Also, the probabil-
ity of further exposure should not be affected by a
previous event (i.e. event-independent exposure assump-
tion) or the design should be adapted as appropriate, as
in excluding person-times before exposure [11, 16, 17].
Finally, the event should not affect the short-term mor-
tality probability, or the analysis should be adapted by
involving the time interval between the event and end of
the actual observation period [11, 16, 19].
All assumptions were mainly assessed on what the au-
thors reported in their paper. With no mention of these
assumptions in the article, the assessment was based on
our own judgement, after consensus: in particular, the
appropriateness of these assumptions can be deduced
for particular studied events (e.g., myocardial infarction,
falls, or febrile convulsions) by referring to several meth-
odological studies with applications to such events [7,
26, 27]. When we could establish no clear conclusion,
the assumption was considered unclear.
Of note, we did not consider that the design adapta-
tion proposed by Wang et al. to study sustained expo-
sures or insidious-onset outcomes (i.e., prolonged
exposure windows) [28] allows for consider them minor
validity assumptions in all situations. In fact, there is still
a validity threat when there is a small probability of
switching between exposure statuses within the observa-
tion window or when the hypothesised effect is of a cu-
mulative nature with a delayed onset. In the former
setting, this design adaptation could lead to loss of stat-
istical power (increasing type II error and false negatives)
because of too many rare discordant cases in case-
crossover studies or unexposed cases in self-controlled
case series. Also, the probability for the occurrence of
time-varying within-person confounders is high, so self--
controlled designs not recommended as compared to
cohort-based approaches in such situations.
For articles with several outcomes, we considered the
assumptions valid if they were fulfilled for at least one
outcome. Finally, we considered that a study did not
fulfil minor assumptions if at least one of the assump-
tions was violated.
Quality of reporting
We examined whether the recommendations from
Nordmann et al. [6] were applied for quality of report-
ing. These recommendations include the reporting of
the fulfilment of key assumptions (whether the setting
was valid for the design implementation in terms of
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major and minor assumptions); the definition (number
and duration) of the case period (for case-crossover) or
risk period (for self-controlled case series) and the
control periods; the appropriate statistical model (i.e.
conditional logistic regression model or conditional
Poisson regression model for case-crossover [29, 30],
and conditional Poisson regression model, Cox’s strati-
fied proportional hazards model or conditional logistic
regression model for self-controlled case series [30]), an
a priori sample size calculation (or power calculation,
because sample size cannot be chosen in healthcare
database research); the appropriate effect estimator (i.e.
odds ratio for case-crossover and incidence rate ratio for
self-controlled case series) with a measure of variability
(confidence interval or standard deviation); unadjusted
and adjusted estimators; the person-time in each risk
and control period for self-controlled case series; and
finally, the reporting of any sensitivity analyses.
Statistics
The data are described as number (%). Concerning the
exposure characteristics, “one shot”, “transient” and
“intermittent” exposure categories were grouped as
“intermittent”. To describe the appropriate of use of the
self-controlled designs, we determined whether the
major validity assumptions were fulfilled. Furthermore,
we determined whether fulfilment of the minor validity
assumptions was reported in articles reporting valid
major assumptions and also overall. When the fulfilment
of the assumptions was unclear, we considered them
valid in our main analysis. We further performed a sen-
sitivity analysis considering such unclear assumptions as
invalid. Another sensitivity analysis was performed
considering only one article in case of several papers
from the same author(s) with similar objectives. The
quality of reporting was also reported. Analyses involved
use of R 2.15.2 (The R Foundation for Statistical
Computing). The results of our systematic review were
reported according to the PRISMA guidelines [31].
Results
We identified 107 articles describing self-controlled
designs: 53 case-crossover and 55 self-controlled case
series (one study used both designs, Fig. 1). The list of
included articles is reported in Additional file 1: S3.
Their characteristics are reported in Table 1. All papers
were of drug safety.
The fulfilment of the major and minor validity
assumptions for the use of a self-controlled design is
described in Table 2 and reported in details in
Additional file 1: S4a and S4b. Overall, 18 (34%) articles
using a case-crossover design and 7 (13%) articles using
a self-controlled case series did not fulfil all of the major
validity assumptions for their use: most frequently, the
studies examined the effect of a sustained exposure (e.g.,
antihypertensive drugs or platelet aggregation inhibitors
in cardiovascular primary prevention), and 3 examined
an event with an insidious onset (e.g., depression,
chronic fatigue syndrome or congenital malformation).
Classification of exposure was unclear in 8 articles using
a case-crossover design and 1 article using a self-
controlled case series design. Among the 35 case-
crossover studies with valid major assumptions, 4 did
not fulfil the minor ones: a time trend in exposure was
not accounted for in 3, and the opportunity of exposure
could vary between case and control periods in another.
Among the 48 self-controlled case series with valid
major assumptions, 14 did not fulfil the minor ones: 1
study examined an event with recurrences that were not
independent (i.e., migraine), 6 studies violated the as-
sumption of event-independent exposure and 8 studies
examined an outcome that could censor the observation
period (such as myocardial infarction, stroke, heart fail-
ure). An exposure temporal trend was unclear or not re-
ported in 22 articles using a case-crossover design.
Overall, all the assumptions were fulfilled in 31 (58%)
case-crossovers studies and 34 (62%) self-controlled case
series. Considering unclear assumptions as invalid led to
smaller proportions of appropriate studies, especially for
case-crossover designs (Additional file 1: S5). Of note, a
sensitivity analysis considering only one article when
several from the same author(s) with similar objectives
were included in the systematic review showed similar
results (Additional file 1: S6).
Considering the quality of reporting (Table 3), the as-
sumptions for use of a self-controlled design were
reported in 53 (50%) papers (at least one major assump-
tion reported in 41, at least one minor assumption in 8,
and both major and minor assumptions reported in 4).
In 9 papers stating that the use of a self-controlled
design was adequate with regard to major assumptions,
the studied exposure was actually sustained. Overall, 94
(88%) papers reported a rationale for using a self-
controlled design (i.e., to account for confounding fac-
tors that do not change over time). The definition of the
control periods was unreported in 3 (6%) papers
describing a case-crossover design and 6 (11%) a self-
controlled case series. The model used was reported in
93% of articles and was appropriate in 100% of these.
The sample size or post-hoc power calculation was
reported in 12% of articles. The results were always dis-
played with a measure of variability, but in 37 (66%) of
the self-controlled case series, the person-time in each
period was not reported. Two thirds of articles reported
adjusted estimates (with or without unadjusted esti-
mates). Sensitivity analyses were described in half of the
articles and well reported. Three articles reported all the
recommended quality items.
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Discussion
In this review of articles, we quantified the appropriate
use of self-controlled designs in pharmacoepidemiology
involving electronic healthcare databases in terms of
major and minor validity assumptions for the use of the
designs. We focused on studies involving medical data-
bases, in which self-controlled designs are particularly
useful to adjust for time-invariant confounders that may
not be collected. Self-controlled designs were not appro-
priately used in 34% and 13% of the articles we reviewed
that described a case-crossover or self-controlled case
series design, respectively. We encourage better use of
these designs for situations in which major validity
assumptions are fulfilled (i.e., for which they are recom-
mended), accounting for situations for which the design
can be adapted.
Our study updated the Nordmann et al. review [6] and
is the first systematic review exploring the appropriate
use of self-controlled designs in pharmacoepidemiology
involving electronic healthcare databases, in terms of
major and minor validity assumptions, in accordance
with recent recommendations. The fulfilment of major
assumptions is the minimum requirement for self-
controlled designs to be valid, as they can be superior to
designs with comparison groups in such situations
(more powered and less biased) [5]. Moreover, recent
recommendations state that the self-controlled designs
should be preferred to designs with comparison groups
in studies performed on healthcare databases, when key
validity assumptions are fulfilled [4]. For articles that did
not fulfil all of the major validity assumptions, it was
essentially due to the study of sustained exposure (e.g.,
antihypertensive drugs or prophylaxis for cardiovascular
events) or events with an insidious onset (depression or
chronic fatigue). The intermittency of exposure is a
requirement for both case-crossover and self-controlled
case series to ensure that the number of patients with
varying exposure statuses is not too small [4]. The acute-
ness of the event onset is a validity assumption that
reduces the likelihood of misclassification bias [32].
However, some have proposed an adaptation of the case-
crossover design for studying prolonged exposures and
insidious-onset outcomes [28] and an adaptation of the
self-controlled case series (towards the end of our obser-
vation period) for studying cumulative exposure [33].
The design adaptation Wang et al. proposed consists of
lengthening exposure assessment windows [28]. Despite
these adaptations, self-controlled designs are usually less
Fig. 1 Flow chart of the selection of articles
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powered than between-person comparisons when study-
ing sustained exposures, because discordant pairs sel-
dom arise when exposures are actually sustained and the
observation period is short as compared to the risk and
control period durations. Thus, both case-crossover and
self-controlled case series designs would fail: the former
because of a too-small number of discordant pairs and
the latter because cases would be seldom unexposed.
Hence, self-controlled designs are not recommended for
situations of sustained exposure because they could lead
to a loss of power [4]. In fact, few statistical power (or
sample size) calculations were carried out in the in-
cluded studies so the impact of studying long-term ex-
posures when there is a low probability of switching is
uncertain. In addition, lengthening exposure assessment
windows increases the risk of bias due to within-person
time-varying confounders (the absence of which is the
main advantage of using self-controlled designs). Even if
lengthening exposure assessment windows reduces mis-
classification bias, it does not answer the issue of reverse
causality that could arise when an exposure occurs after
the true time of outcome onset, thereby leading to a
spurious association. More generally, failure to meet
important assumptions of self-controlled designs has been
associated with increased risk of discrepant results between
case-only and cohort-based approaches (which can occur
even in the absence of unmeasured confounders) [30].
For all these reasons, we considered that studies
involving a self-controlled design were invalid in situa-
tions of sustained exposure when there was a small
probability of switching between exposure status within
the observation window or when the outcome has an
insidious or delayed onset or results from a cumulative
effect. Of note, we classified drugs that are usually used
chronically as “intermittent exposures” when a high
opportunity for a switch from exposed to unexposed
status (or vice versa) can be assumed over the observa-
tion period. Several examples can be cited: methylphen-
idate in children with attention-deficit/hyperactivity
disorder (the treatment is usually discontinued during
holidays) and palivizumab, an anti-respiratory syncytial
virus (RSV) monoclonal antibody for prophylaxis of
severe lower respiratory tract infection in children
(usually administered during the high-risk season of
RSV infection).
In a sensitivity analysis, considering studies examining
a sustained exposure as appropriate (without accounting
for the probability of switching exposure status), 45
(85%) case-crossover and 53 (96%) self-controlled case
series studies fulfilled all major assumptions. In this ana-
lysis, the most frequent validity threats were insidious or
common events.
In terms of event frequency, we considered rare and/
or recurrent events as appropriate for self-controlled
case series and only rare events for case-crossover
designs. However, in situations when the event is both
non-recurrent and non-rare, a self-controlled design can
still be used. Nevertheless, this use would imply that the
number of strata (here, the number of cases) would
increase but not their size (here, the number of periods
within the same patient), thereby leading to poor estima-
tion of the variance when using stratified models. There-
fore, we considered the rare or recurrent event as a
major assumption. Moreover, in the study of Pouwels et
al., the rareness of the outcome was a factor associated
with fewer discrepancies [30].
We found that minor assumptions were most often
valid when major ones were valid. As a reminder, those
assumptions were considered minor because the design
can be adapted if they are not fulfilled, which allows for
a self-controlled design. A small proportion of the self-
controlled designs, 18 (16%), could have been improved
by applying those adaptations. For instance, 3 studies
with a case-crossover design did not adjust for a time
Table 1 Characteristics of 107 studies with self-controlled
designs
Publication journal topic categories
Specialized journal 48 (45)
Pharmacology or epidemiology journal 43 (40)
General medicine journal 16 (15)
Studied exposure
Vaccines 30 (28)
Psychotropic medications 25 (23)
Cardiovascular drugs (including anticoagulant or
anti-platelet, antihypertensive and hypoglycaemic drugs)
15 (14)
Anti-infective agents 9 (8)
Analgesics 7 (7)
Gastroenterologic medications 6 (6)
Others 15 (14)
Studied eventa
Cardiovascular event 29 (27)
Neuro / psychological event 16 (15)
Hospital admission or emergency visit 13 (12)
Gastrointestinal event 12 (11)
Fractures, injury 8 (7)
Pneumological event 7 (7)
Traffic accident 6 (6)
Fall 4 (4)
Nephrological event 4 (4)
Deep vein thrombosis / pulmonary embolism 3 (3)
Other 10 (9)
Data are reported as n (%)
aTotal can be more than 100% if several outcomes were studied in the
same study
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trend in exposure, even though the paper clearly stated
that such a trend existed. It has been shown that lack of
adjustment for exposure time-trends in case-crossover
studies led to biased estimations [14, 25, 34], and hence
several extensions of the case-crossover design have
been developed to take into account a temporal trend in
exposure [14, 15, 24, 25]. Of note, in 22 additional
papers from our systematic review, the existence of an
exposure time-trend was not discussed by the authors
nor could be assessed from the reported information,
but we still considered them appropriate. Thus, the
proportion of case-crossover studies that could have
used the design more adequately may be underesti-
mated. Researchers must keep in mind that the explor-
ation and reporting of such a trend in case-crossover
studies is crucial for design validity. Concerning the
event-independent exposure assumption, we found that
it was fulfilled in 88% of articles involving a self-
controlled case series. A simulation study reported that
relative incidence is almost always overestimated when




N = 53 N = 55
Major assumptions:
Type of studied exposure
Intermittent/transient 34 (64) 49 (89)
Sustained 11 (21) 5 (9)
Unclear 8 (15) 1 (2)
Event onset
Abrupt 52 (98) 53 (96)
Insidious 1 (2) 2 (4)
Rare event 46 (87) 48 (87)
Recurrent event
(for self-controlled case series only)
- 42 (76)
Rare and/or recurrent event (for
self-controlled case series only)
- 55 (100)
All major validity assumptions fulfilleda 35 (66) 48 (87)
Minor assumptions:
Same opportunity of exposureb 34/35 (97) -
Time trend in exposure
Yes 8/35 (23) -
In case of exposure time trend, the
design is adapted
5/8 (63)
No 5/35 (14) -
Unclear 22/35 (63) -
Absence of exposure time trend (or
design adapted)
32/35 (91)
Independence of consecutive events
Yes - 5/48 (10)
No - 17/48 (35)
For non-independent recurrences,
the design is adapted
16/17 (94)




Independence of consecutive events
when recurrent (or design-adapted)c
- 47/48 (98)
Event-independent exposure
Yes - 5/48 (10)
No - 38/48 (79)
For non-event-independent
recurrences, the design is adapted
32/38 (84)




The event affects the short-term
mortality probability (censoring of
the observation period)
-
Yes - 12/48 (25)
Table 2 Fulfilment of the validity assumptions for the use of a
self-controlled design (Continued)
For event-dependent censoring,
the design is adapted
4/12 (33)
No - 36/48 (75)
Absence of censoring the observation
period (or design-adapted)e
- 40/48 (83)
All minor validity assumptions fulfilled
for use of a self-controlled design
(among articles with valid major
assumptions)f
31/35 (89) 34/48 (71)
All major and minor validity
assumptions fulfilled for use of a
self-controlled design
(among all articles)
31/53 (58) 34/55 (62)
Data are reported as n (%)
aFor case-crossover design, a transient or intermittent exposure, an abrupt
onset event, and a rare event. For self-controlled case series, a transient or
intermittent exposure, an abrupt onset event, and a rare and/or recurrent
event. Unclear exposures were considered intermittent
bSame opportunity of exposure during case and control time periods
cThis assumption is fulfilled for studies examining non-recurrent events,
recurrent events with independence between consecutive events, or
non-independent recurrences when the design is adapted, or recurrent events
for which independence is unclear
dThis assumption is fulfilled for studies examining exposure whose probability
is not affected by previous events, with an adapted design when probability
of exposure is affected by a previous event, or with unclear
event-independent exposures
eThis assumption is fulfilled for studies examining outcomes that do not
censor the observation period by affecting the short-term mortality probability
or with an adapted design when the observation period can be censored by
the outcome
fFor case-crossover design, the opportunity for exposure should be the same
during the case and control time periods, and there should not be any time
trend in exposure. For self-controlled case series, two consecutive events
should be independent if they are recurrent; the probability of further
exposure should not be affected by a previous event; and the event should
not affect the short-term mortality probability nor censor the observation
period. In case of violation of one of these assumptions, the design should
be adapted
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the event-independent exposure assumption is violated
in self-controlled case series studies (except for the situ-
ation of extreme dependence), but the bias is corrected
when the design is adapted [35]. The corresponding
methodological developments were published in the late
2000s [11, 16], perhaps too recently to be applied in the
studies we reviewed.
Of note, a simulation study explored the validity of
the case-time-control design in situations of within-
individual exposure dependency over several control
periods but showed that the method is robust to de-
viation of this assumption [36]. We did not explore
this assumption the studies included in our review.
The previous systematic review by Nordmann et al.
reported the validity assumptions of self-controlled de-
signs in pharmacoepidemiology between 1995 and 2010
(before the development of the previously cited recom-
mendations) [6]. The authors reported an inappropriate
use of self-controlled designs: validity assumptions were
not fulfilled for 76% of the articles describing a case-
crossover design and 60% self-controlled case series.
Concerning major assumptions, our review, which cov-
ered healthcare database studies published recently,
shows that these data have improved. Moreover, major
and minor validity assumptions were not distinguished
in the Nordmann et al. review. Nevertheless, we found
the same main reasons for the inappropriate use of these
designs (i.e., the study of sustained exposure and the
absence of considering exposure time-trend).
Self-controlled designs can control for intra-individual
time-invariant confounders. Many design extensions that
weaken the validity assumptions have been developed, and
these designs still are under development, such as for the
study of multiple exposures [37], or the study of recurrent
events when recurrences are not independent [27]. How-
ever, the designs are subject to several biases (e.g., residual
confounding due to unmeasured within-person time-
varying factors or misclassification of exposure [32]).
Moreover, self-controlled designs explore the triggers that
precede abrupt-onset events, and answer the questions
“Why now?” or “What happened just before?”, which is
slightly different from the question raised with between-
person comparisons (“Why me?”) [38]. Nevertheless, they
are complementary to cohort-based approaches [4], and
both designs should be applied, especially when one or
more assumptions are not fulfilled [30].
Regarding the quality of reporting, we found 9 studies
examining sustained exposures (e.g., antihypertensive
treatments or low-dose aspirin for secondary prevention
of cardiovascular events), which indicates the reporting
of the design being appropriate to study abrupt-onset
outcome and transient drug exposure. This high number
underlines that authors and reviewers should be aware
of the design’s validity assumptions, recommendations
for use and the need to report validity assumptions
fulfilled (or not). Indeed, the minor assumptions were
rarely reported in the papers we reviewed. In addition,
the sample size or power calculation was rarely reported,
with no improvement compared to a previous review
[6]. However, studies involving electronic healthcare
databases usually have very large sample sizes and
perhaps the sample size calculation is not needed in this
context, because the sample size cannot be chosen.
However post-hoc power calculation in the database
study sample is important to decide which healthcare
database should be used and to interpret the absence of
a statistical association, especially in the context of a
very rare event. Post-hoc power calculation indicates
how easily an effect that is fixed a priori can be shown
(accounting for the observed number of patients/cases
and the observed variability). Even if confidence intervals
(which represent how accurate the results are estimated)
are reported, the power calculation is more related to
the number of observed events, and is information that
is easier for the reader to understand: in case of non-
significant associations, power can be quite difficult to
interpret on the basis of the sole confidence interval.
Table 3 Quality of reporting
Required items to be reported in the
Method section
Assumptions for the use of a self-controlled design
(whether the setting is valid for the design
implementation, with regard to major assumptions)
53 (50)
Case and control period definition (including
number and duration) for case-crossover studies
50/53 (94)
Risk and control period definition (including number





Statistical model 99 (93)
With the appropriate modela 99/99 (100)
Effect estimator 107 (100)
Sample size or power calculation 13 (12)
Result section
Appropriate effect estimator with a measure
of variability
102 (95)
Person-time in the different periods
(for self-controlled case series)
18/55 (33)
Estimate displayed
Unadjusted effect estimators 36 (34)
Adjusted effect estimators 38 (36)
Both unadjusted and adjusted effect estimators 33 (31)
Data are reported as n (%)
aConditional logistic regression or conditional Poisson regression model for
case-crossover studies, conditional Poisson regression model, Cox’s stratified
proportional hazards model or conditional logistic regression model for
self-controlled case series
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With respect to other elements of reporting quality, a
measure of variability of the estimate was always reported,
which we considered adequate if the number and duration
of different periods were also reported. The effect estima-
tor was not always appropriately reported, but reported
statistical models were all considered as appropriate. Valid
models other than the conditional logistic regression or
the conditional Poisson regression can still be applied,
such as the Cox stratified proportional-hazards model for
case-crossover studies and the Cox stratified or condi-
tional logistic regression models for self-controlled case
series [30], even if unusual. However, it has been shown
that in case-crossover studies, for instance, conditional
logistic regression model and conditional Poisson model
give identical estimates [29]. In case-crossover studies,
times to event are the same for case and control periods
(because periods are defined similarly within strata) and
even if a stratified Cox model can be used, it does not
assess and compare a time to event. Therefore, the estima-
tor computed (even if called a “hazard ratio”) still repre-
sents an “odds ratio” and should be interpreted as such.
One third of the included papers reported both adjusted
and unadjusted estimates, which is quite low when they
allow for assessing the importance of bias. Nordmann et
al. recommended that the number of discordant pairs in
case-crossover designs (i.e., number of patients who
crossed from unexposed in the control period to exposed
in the case period, or vice versa [8]), or the count of
events in the different time periods for self-controlled case
series should be reported [6]. We considered that these
items need to be reported, except if a measure of variabil-
ity of the estimate is reported along with a clear descrip-
tion of the number and duration of different periods.
However, only a small number of self-controlled case
series reported the duration of control period along with
the person-times in risk and control periods, but this was
appropriately reported for case-crossover studies. Conse-
quently, the quality of reporting in self-controlled studies
can still be improved, in accordance with the recommen-
dations provided by Nordmann et al. [6].
Our study has some limitations. First, a potential paper
selection bias could exist, which we tried to limit with a
comprehensive literature search using keywords, title and
abstract terms, and few limits, that were already used in
previous systematic reviews [6, 30, 39]. Moreover, the def-
inition of abrupt versus insidious onset of the event is
somewhat subjective, as is transient versus sustained
exposure, or some minor assumptions for the self-
controlled case series. We tried to limit this issue by
consensus. Some strengths of this study are worth noting.
We focused on studies involving medical databases
because of a growing interest in the use of “big data” in
healthcare research [40]. We updated Nordmann et al.
review [6] up to 2014, and to ensure that no indexing issue
in PubMed can be suspected, we updated our literature
search in July 2016.
Conclusion
Self-controlled designs have many advantages, including
their ability to inherently adjust for time-invariant factors,
which is important when using electronic healthcare
databases, where some confounding factors are usually
not collected or nor available. We found that in terms of
fulfilling the major assumptions of the designs, the designs
for one-third of the case-crossover studies and less than
one-fifth of self-controlled case series we reviewed were
not appropriately used in these pharmacoepidemiology
studies involving electronic healthcare databases. We
encourage a better justification of the design validity in
terms of major and minor assumptions in accordance with
recommendations for their use and more accurate report-
ing of self-controlled case series. Addressing these issues
will contribute to a wiser use of these self-controlled
designs, which is advantageous for pharmacoepidemiology
involving large healthcare databases.
Endnotes
1In some articles of self-controlled case series, the risk
period was defined arbitrarily in the same way for all
patients without accounting for the actual duration of
prescription. For drugs used chronically, this situation
can result in misclassification bias, because the subject is
considered unexposed when a prescription period was
still ongoing. Such exposures were considered sustained
and the design was considered as inappropriate in these
situations. In contrast, when risk period was equal to the
prescription period and when the observation period
was large enough to observe a switch in exposure status,
we considered the exposure as transient even if it was
used chronically
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